Two people can hold the identical prescription and receive opposite answers about coverage, simply because they live in different states. That outcome is not an accident of modern politics. It traces back through decades of federal law, each piece adding another layer to how drugs reach pharmacies, who can prescribe them, and who decides whether an insurer has to pay. Understanding that history helps explain why your ZIP code, not just your diagnosis, so often decides your access to a GLP-1.
Before any GLP-1 could reach a pharmacy shelf, it had to clear a review process that did not exist before 1938. The Federal Food, Drug, and Cosmetic Act created the requirement that the FDA examine a drug's safety before it enters the market, and that same requirement still governs every GLP-1 sold today. This is a baseline that applies everywhere: no state, insurer, or employer gets to decide whether the drug is safe enough to exist, because federal law settled that question long ago. What varies by state, as later law makes clear, is a narrower question: whether someone will pay for it once it has been approved.
Thirteen years later, the Durham-Humphrey Amendment changed how a patient could obtain a GLP-1 at all. The 1951 law established that certain drugs, including what would become GLP-1s, could only be dispensed with a physician's prescription. That requirement means a doctor's diagnosis, not just a patient's request, determines whether a prescription can be written in the first place. It also means the diagnosis code attached to that prescription, whether it lists diabetes, cardiovascular risk, or obesity, becomes the detail that insurers and state programs later use to decide whether they will cover the drug.
The 1990 Omnibus Budget Reconciliation Act set up the Medicaid Drug Rebate Program, and this is the law most directly responsible for the state-by-state coverage differences patients see today. The program works as a bargain: drug manufacturers offer rebates to state Medicaid programs, and in exchange, states gain broad discretion over which drugs their Medicaid programs will cover, including for which indications. That discretion is why a minority of states currently cover GLP-1s for weight loss through Medicaid while most do not. It is also why a state can change its mind, as Massachusetts is doing by ending MassHealth coverage for weight-loss-only use in 2026 while keeping coverage for diabetes and other approved indications. The rebate program does not tell any state what to decide. It simply hands the decision to each state and lets the outcomes diverge.
Two years later, the Veterans Health Care Act of 1992 created the 340B Drug Pricing Program, which lets certain safety-net providers, such as community health centers and hospitals serving low-income populations, buy outpatient drugs at reduced prices. Where a GLP-1 is covered, the 340B program can lower the cost of getting it, but only at qualifying clinics. That means two patients with identical insurance coverage can still pay different amounts depending on whether the clinic filling their prescription participates in 340B. It also means the address of your clinic, separate from the address of your state, can affect what you pay.
By 2012, Congress recognized that coverage decisions mean little if the drug itself is not available, so the FDA Safety and Innovation Act gave the FDA formal authority to manage drug shortages. Under this law, the FDA can require manufacturers to report anticipated supply disruptions and can work to prevent or shorten shortages once they start. GLP-1 demand has strained manufacturing capacity in recent years, and this authority is part of what determines whether a covered prescription can actually be filled on a given week. Coverage and supply are separate problems, and this 2012 law addresses the second one, not the first.
None of these laws was written with today's obesity-drug debate in mind, yet together they explain why coverage looks so uneven from one state, one clinic, and one diagnosis to the next. If you are trying to get a GLP-1 covered, the practical response is to check the specific layer that applies to you: your state's Medicaid rules if you rely on that program, your plan's formulary if you have marketplace or employer coverage, whether your clinic participates in 340B if cost is the barrier, and whether a shortage is affecting your particular medication. Each of those checks answers a different question, and no single one of them will give you the whole picture on its own. Knowing which law governs which piece of your situation is what turns a frustrating patchwork into something you can actually work through.
Key details
The 1938 FDCA required FDA safety review before your GLP-1 could reach pharmacies.
The 1951 Durham-Humphrey Amendment made your GLP-1 a prescription-only drug.
OBRA 1990's rebate program lets your state Medicaid decide GLP-1 obesity coverage.
The 1992 Veterans Health Care Act's 340B program can cut GLP-1 costs at some clinics.
FDASIA 2012 gave the FDA power to manage drug shortages affecting GLP-1 supply.